Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?

Johnson P, Greiner W, Al-Dakkak I, Wagner S (2015)
BioMed Research International.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ;
Abstract
Patients with certain cancers are treated with curative intent, but for others the results are less favorable and different therapeutic approaches are needed. Early data suggest that new therapies, which modulate immune responses to cancers, may have potential for long-termsurvival in a proportion of cases. Therefore, it is timely to consider whether metrics generally used to describe the medical value of therapies for patients with common solid tumors remain appropriate for therapies with curative potential. Literature reviews were conducted to define how various stakeholders describe cure in oncology and to identify the endpoints used in clinical trials for selected solid tumors. The results showed that "cure" is described using various terms that can be divided broadly into lack of disease progression, eradication of cancerous cells, and survival. The review of trial endpoints showed frequent use of median overall survival (OS) and progression-and response-related endpoints. Because these endpoints were mainly described in the context of chemotherapies that are not generally curative, they may not adequately capture outcomes of new therapeutic modalities with potential for long-term survival. More appropriate endpoints may include mean OS, cure fraction, and OS rate at landmark time points.
Publishing Year
ISSN
PUB-ID

Cite this

Johnson P, Greiner W, Al-Dakkak I, Wagner S. Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies? BioMed Research International. 2015.
Johnson, P., Greiner, W., Al-Dakkak, I., & Wagner, S. (2015). Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies? BioMed Research International.
Johnson, P., Greiner, W., Al-Dakkak, I., and Wagner, S. (2015). Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies? BioMed Research International.
Johnson, P., et al., 2015. Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies? BioMed Research International.
P. Johnson, et al., “Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?”, BioMed Research International, 2015.
Johnson, P., Greiner, W., Al-Dakkak, I., Wagner, S.: Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies? BioMed Research International. (2015).
Johnson, Peter, Greiner, Wolfgang, Al-Dakkak, Imad, and Wagner, Samuel. “Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?”. BioMed Research International (2015).
This data publication is cited in the following publications:
This publication cites the following data publications:

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Search this title in

Google Scholar